GLUE Monte Rosa Therapeutics, Inc. Forward P/S Multiple

Monte Rosa Therapeutics (GLUE) strengthens physician confidence through its pioneer status in protein degradation, which is driving the forward revenue multiple higher. The development of molecular glues is supported by a team of PhD specialists, while a strategic alliance with a pharma behemoth mitigates pipeline risks. The current value of the metric is 11.30, which this chart reflects as the dynamics of the company's market valuation relative to expected future earnings.

GLUE (monterosatx.com) Price to Expected Revenue Ratio history from 05/11/2024 to 11/13/2026

Monte Rosa Corp - analytical breakdowns and key metrics (GLUE)

- current price and projected stock value:

Stock Price Monte Rosa Therapeutics, Inc.|GLUE - Analyst Target Range

- market capitalization data:

Market Capitalization Monte Rosa Corp|GLUE - Total Enterprise Value

- issuer book value statistics:

Accounting Value per Share Monte Rosa Therapeutics|GLUE - Total Net Assets|Market Capitalization to Book Value Ratio monterosatx.com|GLUE - Company Assets

- debt and liquidity data:

- net income and valuation multiples indicators:

GLUE - Company Net Income|Expected Profit Monte Rosa Therapeutics|GLUE - Company Value to Net Income|Forward P/E Multiple Monte Rosa Tx|GLUE - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Monte Rosa Corp|GLUE - Profit before deduction of interest, taxes, depreciation and amortization|Net earnings per share for the last 12 months Monte Rosa Therapeutics|GLUE - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months monterosatx.com|GLUE - Net earnings per share growth this year|Net earnings per share growth forecast for next year Monte Rosa Therapeutics

- issuer revenue and sales details:

GLUE - Company Total Revenue|Company Projected Revenue Monte Rosa Therapeutics, Inc.|GLUE - Market Cap to Revenue Ratio|Forward Price-to-Revenue Multiple Monte Rosa Corp

Summary company analysis:Monte Rosa Therapeutics, Inc. (GLUE)

The forward P/S ratio measures market capitalization relative to expected sales volume, determining the premium for future growth and revenue resilience against external shocks. By analyzing the forward P/S ratio, an investor assesses how effectively protein synthesis automation and AI design at Monte Rosa Therapeutics (GLUE) convert into capitalization, accounting for the risks of delays due to the mandatory involvement of physicians in clinical trials.

Competing companies

Forward P/S Multiple GMAB (Genmab)|Projected Price to Revenue Exelixis Inc|Nuvalent Corp - Forward P/S Multiple|Market Cap to Future Revenue Ratio Kymera Corp|IDYA (IDEAYA Biosciences) - Forward Price-to-Revenue Multiple|ELVN: Price to Expected Revenue Ratio|ORIC (ORIC Pharmaceuticals, Inc.) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Relay Therapeutics Inc RLAY|Forward P/S Multiple NRIX|Tyra Corp - Market Cap to Projected Revenue|Verastem, Inc. - Forward Price-to-Revenue Multiple|Forward Price to Sales CGEM|IMRX: Forward Price-to-Revenue Multiple|C4 Therapeutics Inc - Price to Expected Revenue Ratio|BDTX: Forward P/S Multiple|Repare Therapeutics Inc - Forward Price to Sales|PMVP (PMV Pharmaceuticals) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Karyopharm KPTI|Price-to-Projected Revenue Ratio Propanc Biopharma Inc (PPCB)|BGMS (Bio Green Med Solution Inc.) - Forward Price to Sales|Forward P/S Multiple AADI (Aadi Bioscience, Inc.)|Forward P/S Multiple Aileron Therapeutics Inc ALRN|BPMC - Price-to-Projected Revenue Ratio|Future Price to Revenue GLYC|SWTX (SpringWorks Therapeutics, Inc.) - Forward Price-to-Revenue Multiple